Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

被引：21

作者：

Wensink, G. Emerens ^{[1
]}

Elferink, Marloes A. G. ^{[2
]}

May, Anne M. ^{[3
]}

Mol, Linda ^{[2
]}

Hamers, Patricia A. H. ^{[1
]}

Bakker, Sandra D. ^{[4
]}

Creemers, Geert-Jan ^{[5
]}

de Groot, Jan Willem B. ^{[6
]}

de Klerk, Gerty J. ^{[7
]}

Haberkorn, Brigitte C. M. ^{[8
]}

Haringhuizen, Annebeth W. ^{[9
]}

Hoekstra, Ronald ^{[10
]}

Hunting, J. Cornelis B. ^{[11
]}

Kerver, Emile D. ^{[12
]}

Mathijssen-van Stein, Danielle ^{[13
]}

Polee, Marco B. ^{[14
]}

Pruijt, Johannes F. M. ^{[15
]}

Quarles van Ufford-Mannesse, Patricia ^{[16
]}

Radema, Sandra ^{[17
]}

Rietbroek, Ronald C. ^{[18
]}

Simkens, Lieke H. J. ^{[19
]}

Tanis, Bea C. ^{[20
]}

ten Bokkel Huinink, Daan ^{[21
]}

Tjin-A-Ton, Manuel L. R. ^{[22
]}

Tromp-van Driel, Cathrien S. ^{[23
]}

Troost, Monique M. ^{[24
]}

van de Wouw, Agnes J. ^{[25
]}

van den Berkmortel, Franchette W. P. J. ^{[26
]}

van der Pas, Anke J. M. ^{[27
]}

van der Velden, Ankie M. T. ^{[28
]}

van Dijk, Marjan A. ^{[29
]}

van Dodewaard-de Jong, Joyce M. ^{[30
]}

van Druten, Edith B. ^{[31
]}

van Voorthuizen, Theo ^{[32
]}

Jan Veldhuis, Gerrit ^{[33
]}

Verheul, Henk M. W. ^{[34
]}

Vestjens, Hanneke J. H. M. J. ^{[25
]}

Vincent, Jeroen ^{[35
]}

Kranenburg, Onno W. ^{[36
,37
]}

Punt, Cornelis J. A. ^{[38
]}

Vink, Geraldine R. ^{[1
,2
]}

Roodhart, Jeanine M. L. ^{[1
]}

Koopman, Miriam ^{[1
]}

机构：

[1] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands

[2] Netherlands Comprehens Canc Org, Dept Res, Postbus 19079, NL-3501 DB Utrecht, Netherlands

[3] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands

[4] Zaans Med Ctr, Dept Med Onco, Postbus 210, NL-1500 EE Zaandam, Netherlands

[5] Catharina Hosp, Dept Med Oncol, Postbus 1350, NL-5602 ZA Eindhoven, Netherlands

[6] Isala Hosp, Dept Med Oncol, Dokter Heesweg 2, NL-8025 AB Zwolle, Netherlands

[7] Spaarne Gasthuis, Dept Med Oncol, Spaarnepoort 1, NL-2134 TM Hoofddorp, Netherlands

[8] Maasstad Hosp, Dept Med Oncol, Postbus 9100, NL-3007 AC Rotterdam, Netherlands

[9] Hosp Gelderse Vallei, Dept Med Oncol, Willy Brandtlaan 10, NL-6716 RP Ede, Netherlands

[10] Ziekenhuisgroep Twente, Dept Med Oncol, Postbus 7600, NL-7600 SZ Almelo, Netherlands

[11] Antonius Hosp, Dept Med Oncol, Postbus 2500, NL-3430 EM Nieuwegein, Netherlands

[12] OLVG, Dept Med Oncol, Oosterpark 9, NL-1091 AC Amsterdam, Netherlands

[13] Franciscus Gasthuis & Vlietland, Dept Med Oncol, Vlietlandpl, NL-3118 JH Schiedam, Netherlands

[14] Med Ctr Leeuwarden, Dept Med Oncol, Postbus 888, NL-8901 BR Leeuwarden, Netherlands

[15] Jeroen Bosch Hosp, Dept Med Oncol, Postbus 90153, NL-5200 ME Shertogenbosch, Netherlands

[16] HagaZiekenhuis, Dept Med Oncol, Els Borst Eilerspl 275, NL-2545 AA The Hague, Netherlands

[17] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Postbus 9101, NL-6500 HB Nijmegen, Netherlands

[18] Rode Kruis Hosp, Dept Med Oncol, Postbus 1074, NL-1940 EB Beverwijk, Netherlands

[19] Maxima Med Ctr, Dept Med Oncol, Postbus 90052, NL-5600 PD Eindhoven, Netherlands

[20] Groene Hart Hosp, Dept Med Oncol, Bleulandweg 10, NL-2803 HH Gouda, Netherlands

[21] Diakonessenhuis Utrecht, Dept Med Oncol, Postbus 80250, NL-3508 TG Utrecht, Netherlands

[22] Hosp Rivierenland, Dept Med Oncol, President Kennedylaan 1, NL-4002 WP Tiel, Netherlands

[23] Gelre Hosp, Dept Med Oncol, Postbus 9014, NL-7300 DS Apeldoorn, Netherlands

[24] Bravis Hosp Bergen Zoom, Dept Med Oncol, Postbus 999, NL-4700 AZ Roosendaal, Netherlands

[25] VieCuri Med Ctr, Dept Med Oncol, Postbus 1926, NL-5900 BX Venlo, Netherlands

[26] Zuyderland Med Ctr Heerlen, Dept Med Oncol, Postbus 5500, NL-6130 MB Geleen, Netherlands

[27] LangeLand Hosp, Dept Med Oncol, Postbus 3015, NL-2700 KJ Zoetermeer, Netherlands

[28] Tergooi, Dept Med Oncol, Riebeeckweg 212, NL-1213 XZ Hilversum, Netherlands

[29] ZorgSaam Hosp, Dept Med Oncol, Wielingenlaan 2, NL-4535 PA Terneuzen, Netherlands

[30] Meander Med Ctr, Dept Med Oncol, Postbus 1502, NL-3800 BM Amersfoort, Netherlands

[31] Reinier Graaf Gasthuis, Dept Med Oncol, Postbus 5011, NL-2600 GA Delft, Netherlands

[32] Hosp Rijnstate, Dept Med Oncol, Wagnerlaan 55, NL-6815 AD Arnhem, Netherlands

[33] Antonius Hosp Sneek, Dept Med Oncol, Postbus 20000, NL-8600 BA Sneek, Netherlands

[34] Univ Amsterdam, Med Ctr, Dept Med Oncol, Box 7057, NL-1007 MB Amsterdam, Netherlands

[35] Elkerliek Hosp, Dept Med Oncol, Postbus 98, NL-5700 AB Helmond, Netherlands

[36] Univ Utrecht, Univ Med Ctr Utrecht, Dept Surg Oncol, Postbus 98, NL-5700 AB Utrecht, Netherlands

[37] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht Platform Organoid Technol, Postbus 98, NL-5700 AB Utrecht, Netherlands

[38] Univ Amsterdam, Med Centers, Dept Med Oncol, Postbus 22660, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2021年 / 124卷 / 02期

关键词：

MICROSATELLITE INSTABILITY; POOLED ANALYSIS; BRAF MUTATION; PHASE-III; CAPECITABINE; OXALIPLATIN; MULTICENTER; BEVACIZUMAB; NIVOLUMAB; PROGNOSIS;

D O I：

10.1038/s41416-020-01076-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. Methods Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials;n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. Results Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. Conclusion Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.

引用

页码：399 / 406

页数：8

共 50 条

[31] Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M Koopman
G A M Kortman
L Mekenkamp
M J L Ligtenberg
N Hoogerbrugge
N F Antonini
C J A Punt
J H J M van Krieken
British Journal of Cancer, 2009, 100 : 266 - 273
[32] Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer
Heide, Dana M. van der
Turaga, Kiran K.
Chan, Carlos H. F.
Sherman, Scott K.
JOURNAL OF SURGICAL RESEARCH, 2021, 266 : 104 - 112
[33] Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
Saberzadeh-Ardestani, Bahar
Jones, Jeremy C.
Hubbard, Joleen M.
McWilliams, Robert R.
Halfdanarson, Thorvardur R.
Shi, Qian
Sonbol, Mohamad Bassam
Ticku, Jonathan
Jin, Zhaohui
Sinicrope, Frank A.
JAMA NETWORK OPEN, 2023, 6 (02) : E230400
[34] Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
Song, Yurong
Kerr, Travis D.
Sanders, Chelsea
Dai, Lisheng
Baxter, Shaneen S.
Somerville, Brandon
Baugher, Ryan N.
Mellott, Stephanie D.
Young, Todd B.
Lawhorn, Heidi E.
Plona, Teri M.
Xu, Bingfang
Wei, Lei
Hu, Qiang
Liu, Song
Hutson, Alan
Karim, Baktiar
Burkett, Sandra
Difilippantonio, Simone
Pinto, Ligia
Gebert, Johannes
Kloor, Matthias
Lipkin, Steven M.
Sei, Shizuko
Shoemaker, Robert H.
FRONTIERS IN ONCOLOGY, 2023, 13
[35] Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience
Jin, Zhaohui
Sanhueza, Cristobal T.
Johnson, Benny
Nagorney, David M.
Larson, David W.
Mara, Kristin C.
Harmsen, William C.
Smyrk, Thomas C.
Grothey, Axel
Hubbard, Joleen M.
ONCOLOGIST, 2018, 23 (09): : 1083 - 1091
[36] Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer
Wong, Vanessa
Loft, Matthew
Kosmider, Suzanne
Wong, Rachel
Shapiro, Jeremy David
Hong, Wei
Jennens, Ross
Tie, Jeanne
Caird, Susan
Steel, Simone Anne
Lee, Belinda
Nott, Louise M.
Khattak, Adnan
Lim, Stephanie Hui-Su
Chong, Geoff
Hayes, Theresa M.
Underhill, Craig R.
McLachlan, Sue-Anne
Rainey, Natalie
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Neoadjuvant immunotherapy for locally advanced/metastatic mismatch repair deficient colorectal cancer: A two-year institutional experience.
O'Neill, Maeve
Larkin, John
McCormick, Paul
Mehigan, Brian
Gillham, Charles
Flannery, Delia
O'Connor, Katrina
Gallagher, David James
O'Kane, Grainne M.
Kelly, Michael E.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 179 - 179
[38] Characteristics of BRAFV600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients
de la Fouchardiere, Christelle
Cohen, Romain
Malka, David
Guimbaud, Rosine
Bourien, Heloise
Lievre, Astrid
Cacheux, Wulfran
Artru, Pascal
Francois, Eric
Gilabert, Marine
Samalin-Scalzi, Emmanuelle
Zaanan, Aziz
Hautefeuille, Vincent
Rousseau, Benoit
Senellart, Helene
Coriat, Romain
Flippot, Ronan
Desseigne, Francoise
Lardy-Cleaud, Audrey
Tougeron, David
ONCOLOGIST, 2019, 24 (12): : E1331 - E1340
[39] Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer
Li, Jianxia
Hu, Huabin
Qin, Ge
Bai, Fan
Wu, Xianrui
Ke, Haoxian
Zhang, Jianwei
Xie, Yuqian
Wu, Zehua
Fu, Yang
Zheng, Hongbo
Gong, Longlong
Xie, Zhi
Deng, Yanhong
CLINICAL CANCER RESEARCH, 2024, 30 (02) : 368 - 378
[40] Immunoediting in untreated mismatch repair deficient colorectal cancer
Grasso, Catherine
Giannakis, Marios
Wells, Daniel
Wheeler, David
Shinbrot, Eve
Zaidi, Syed
Huyghe, Jeroen
Geybels, Milan
Salipante, Stephen
Abril-Rodriguez, Gabriel
Escuin-Ordinas, Helena
Puig-Saus, Cristina
Shin, Daniel Sanghoon
Ogino, Shuji
Ribas, Antoni
Peters, Ulrike
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)

← 1 2 3 4 5 →